Which has better valuation and earnings, GUTS or NSPR?

InspireMD has higher revenue and earnings than Fractyl Health. InspireMD is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health $90K 1,411.99 -$140.95M -$1.29 N/A InspireMD $10.85M 3.07 -$19.92M -$0.73 N/A

Is GUTS or NSPR more profitable?

Fractyl Health has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -4,053.15% -96.41% InspireMD -413.96% -69.42% -57.68%

Is NSPR or HYPR more profitable?

Hyperfine has a net margin of -226.88% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets InspireMD -413.96% -69.42% -57.68% Hyperfine -226.88% -98.83% -67.09%

Do analysts prefer FONR or NSPR?

InspireMD has a consensus target price of $4.50, indicating a potential upside of 533.80%. Given InspireMD's stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings & valuation, FONR or NSPR?

Fonar has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fonar $105.34M 1.12 $8.33M $1.00 19.09 InspireMD $10.85M 3.07 -$19.92M -$0.73 N/A

Is FONR or NSPR more profitable?

Fonar has a net margin of 6.35% compared to InspireMD's net margin of -413.96%. Fonar's return on equity of 4.12% beat InspireMD's return on equity. Company Net Margins Return on Equity Return on Assets Fonar 6.35% 4.12% 3.07% InspireMD -413.96% -69.42% -57.68%

InspireMD (NSPR) Competitors

$0.71 -0.01 (-1.25%)

As of 10:15 AM Eastern

Compare

NSPR vs. MBOT, GUTS, HYPR, LAKE, and FONR

Should you buy InspireMD stock or one of its competitors? MarketBeat compares InspireMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InspireMD include Microbot Medical (MBOT), Fractyl Health (GUTS), Hyperfine (HYPR), Lakeland Industries (LAKE), and Fonar (FONR). These companies are all part of the "medical equipment" industry.

How does InspireMD compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Microbot Medical presently has a consensus target price of $6.63, indicating a potential upside of 251.46%. InspireMD has a consensus target price of $4.50, indicating a potential upside of 533.80%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Microbot Medical has higher earnings, but lower revenue than InspireMD. Microbot Medical is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
InspireMD	$10.85M	3.07	-$19.92M	-$0.73	N/A

In the previous week, Microbot Medical had 2 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for Microbot Medical and 0 mentions for InspireMD. Microbot Medical's average media sentiment score of 1.08 beat InspireMD's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Microbot Medical	Positive
InspireMD	Neutral

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 4.7% of Microbot Medical shares are held by company insiders. Comparatively, 34.1% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Microbot Medical has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Microbot Medical's return on equity of -21.84% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
InspireMD	-413.96%	-69.42%	-57.68%

Microbot Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Microbot Medical beats InspireMD on 9 of the 16 factors compared between the two stocks.

How does InspireMD compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Fractyl Health has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-4,053.15%	-96.41%
InspireMD	-413.96%	-69.42%	-57.68%

Fractyl Health currently has a consensus price target of $5.12, suggesting a potential upside of 539.20%. InspireMD has a consensus price target of $4.50, suggesting a potential upside of 533.80%. Given Fractyl Health's higher possible upside, equities analysts plainly believe Fractyl Health is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

44.8% of InspireMD shares are held by institutional investors. 8.5% of Fractyl Health shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Fractyl Health has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

InspireMD has higher revenue and earnings than Fractyl Health. InspireMD is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,411.99	-$140.95M	-$1.29	N/A
InspireMD	$10.85M	3.07	-$19.92M	-$0.73	N/A

In the previous week, Fractyl Health had 3 more articles in the media than InspireMD. MarketBeat recorded 3 mentions for Fractyl Health and 0 mentions for InspireMD. Fractyl Health's average media sentiment score of 0.88 beat InspireMD's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Overall Sentiment
Fractyl Health	Positive
InspireMD	Neutral

Summary

Fractyl Health and InspireMD tied by winning 8 of the 16 factors compared between the two stocks.

How does InspireMD compare to Hyperfine?

InspireMD (NYSE:NSPR) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

44.8% of InspireMD shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 34.1% of InspireMD shares are held by insiders. Comparatively, 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

InspireMD has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Hyperfine has a net margin of -226.88% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Hyperfine	-226.88%	-98.83%	-67.09%

InspireMD has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	3.07	-$19.92M	-$0.73	N/A
Hyperfine	$11.40M	9.32	-$35.57M	-$0.41	N/A

InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 533.80%. Hyperfine has a consensus target price of $1.78, suggesting a potential upside of 66.67%. Given InspireMD's stronger consensus rating and higher possible upside, research analysts clearly believe InspireMD is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Hyperfine had 2 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for Hyperfine and 0 mentions for InspireMD. Hyperfine's average media sentiment score of 0.44 beat InspireMD's score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Overall Sentiment
InspireMD	Neutral
Hyperfine	Neutral

Summary

InspireMD beats Hyperfine on 8 of the 15 factors compared between the two stocks.

How does InspireMD compare to Lakeland Industries?

Lakeland Industries (NASDAQ:LAKE) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Lakeland Industries has a net margin of -10.87% compared to InspireMD's net margin of -413.96%. Lakeland Industries' return on equity of -6.64% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakeland Industries	-10.87%	-6.64%	-4.13%
InspireMD	-413.96%	-69.42%	-57.68%

Lakeland Industries has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

InspireMD has lower revenue, but higher earnings than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakeland Industries	$192.65M	0.55	-$25.31M	-$2.13	N/A
InspireMD	$10.85M	3.07	-$19.92M	-$0.73	N/A

In the previous week, Lakeland Industries had 5 more articles in the media than InspireMD. MarketBeat recorded 5 mentions for Lakeland Industries and 0 mentions for InspireMD. Lakeland Industries' average media sentiment score of 0.57 beat InspireMD's score of 0.00 indicating that Lakeland Industries is being referred to more favorably in the media.

Company	Overall Sentiment
Lakeland Industries	Positive
InspireMD	Neutral

71.7% of Lakeland Industries shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 3.4% of Lakeland Industries shares are owned by insiders. Comparatively, 34.1% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lakeland Industries currently has a consensus target price of $16.00, suggesting a potential upside of 48.29%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 533.80%. Given InspireMD's stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than Lakeland Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Lakeland Industries beats InspireMD on 8 of the 15 factors compared between the two stocks.

How does InspireMD compare to Fonar?

Fonar (NASDAQ:FONR) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Fonar has a net margin of 6.35% compared to InspireMD's net margin of -413.96%. Fonar's return on equity of 4.12% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
InspireMD	-413.96%	-69.42%	-57.68%

50.6% of Fonar shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 7.9% of Fonar shares are held by company insiders. Comparatively, 34.1% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fonar has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09
InspireMD	$10.85M	3.07	-$19.92M	-$0.73	N/A

In the previous week, Fonar's average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score.

Company	Overall Sentiment
Fonar	Neutral
InspireMD	Neutral

InspireMD has a consensus target price of $4.50, indicating a potential upside of 533.80%. Given InspireMD's stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Fonar has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

Fonar beats InspireMD on 9 of the 14 factors compared between the two stocks.

Get InspireMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NSPR vs. The Competition

Export

Metric	InspireMD	Surgical & medical instruments Industry	Medical Sector	NYSE Exchange
Market Cap	$33.30M	$41.48M	$6.76B	$23.49B
Dividend Yield	N/A	1.08%	2.68%	4.02%
P/E Ratio	-0.95	19.09	26.93	31.32
Price / Sales	3.07	27.96	586.18	20.18
Price / Cash	N/A	18.86	29.22	18.64
Price / Book	0.39	9.23	10.94	4.79
Net Income	-$19.92M	-$20.39M	$3.58B	$1.06B
7 Day Performance	-1.39%	-3.50%	-2.10%	0.19%
1 Month Performance	-2.74%	-1.01%	3.21%	0.28%
1 Year Performance	-69.79%	-9.19%	26.34%	17.22%

InspireMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NSPR InspireMD	3.3619 of 5 stars	$0.71 -1.3%	$4.50 +533.8%	-69.5%	$33.30M	$10.85M	N/A	50
MBOT Microbot Medical	2.3727 of 5 stars	$1.90 -1.6%	$6.63 +248.7%	-28.2%	$129.63M	N/A	N/A	20	Analyst Forecast Gap Up
GUTS Fractyl Health	4.2376 of 5 stars	$0.80 -1.2%	$5.12 +543.2%	-49.9%	$127.86M	$90K	N/A	102
HYPR Hyperfine	2.7888 of 5 stars	$1.22 -3.9%	$1.78 +46.2%	+36.5%	$126.07M	$11.40M	N/A	190	Short Interest Increase
LAKE Lakeland Industries	2.947 of 5 stars	$11.84 -2.4%	$16.00 +35.1%	-23.1%	$119.71M	$192.65M	N/A	2,600	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NSPR) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InspireMD (NSPR) Competitors

NSPR vs. MBOT, GUTS, HYPR, LAKE, and FONR

How does InspireMD compare to Microbot Medical?

Summary

How does InspireMD compare to Fractyl Health?

Summary

How does InspireMD compare to Hyperfine?

Summary

How does InspireMD compare to Lakeland Industries?

Summary

How does InspireMD compare to Fonar?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSPR vs. The Competition

InspireMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InspireMD (NSPR) Competitors

NSPR vs. MBOT, GUTS, HYPR, LAKE, and FONR

How does InspireMD compare to Microbot Medical?

Do analysts recommend MBOT or NSPR?

Which has higher earnings & valuation, MBOT or NSPR?

Does the media favor MBOT or NSPR?

Do insiders & institutionals have more ownership in MBOT or NSPR?

Is MBOT or NSPR more profitable?

Which has more volatility and risk, MBOT or NSPR?

Summary

How does InspireMD compare to Fractyl Health?

Is GUTS or NSPR more profitable?

Do analysts recommend GUTS or NSPR?

Do insiders & institutionals hold more shares of GUTS or NSPR?

Which has more volatility & risk, GUTS or NSPR?

Which has better valuation and earnings, GUTS or NSPR?

Does the media favor GUTS or NSPR?

Summary

How does InspireMD compare to Hyperfine?

Do insiders & institutionals hold more shares of NSPR or HYPR?

Which has more volatility & risk, NSPR or HYPR?

Is NSPR or HYPR more profitable?

Which has stronger earnings and valuation, NSPR or HYPR?

Do analysts prefer NSPR or HYPR?

Does the media favor NSPR or HYPR?

Summary

How does InspireMD compare to Lakeland Industries?

Is LAKE or NSPR more profitable?

Which has more risk and volatility, LAKE or NSPR?

Which has stronger valuation and earnings, LAKE or NSPR?

Does the media refer more to LAKE or NSPR?

Do institutionals & insiders hold more shares of LAKE or NSPR?

Do analysts recommend LAKE or NSPR?

Summary

How does InspireMD compare to Fonar?

Is FONR or NSPR more profitable?

Do insiders and institutionals believe in FONR or NSPR?

Which has preferable earnings & valuation, FONR or NSPR?

Does the media favor FONR or NSPR?

Do analysts prefer FONR or NSPR?

Which has more volatility and risk, FONR or NSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSPR vs. The Competition

InspireMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools